James Bingham Net Worth

James Bingham biography

DR. James B. Bingham Ph.D. serves as Chief Development Officer of the Company. He previously served as our Senior Vice President, Development and Manufacturing from October 2015 to December 2018. Dr. Bingham has also served as President of MMG Biopharmaceuticals Consulting, LLC since November 2008. Prior to joining NextCure, Dr. Bingham held various positions at Amplimmune from 2007 to July 2015, including Senior Vice President of Development, Manufacturing and Quality from January 2013 to July 2015. Dr. Bingham served as Associate Director of Microbial Research & Development at Cambrex Corporation and, after its acquisition of Cambrex, Lonza Group AG from 2006 to 2007. Dr. Bingham also worked for Human Genome Sciences, Inc. (acquired by GlaxoSmithKline plc) ("HGS"), from 2000 to 2006. Prior to joining HGS, Dr. Bingham was also employed at MedImmune and Integrated Genetics (now part of Laboratory Corporation of America Holdings). Dr. Bingham received a B.S. in biology from St. Michael's College and a Ph.D. in biological chemistry from The Johns Hopkins University.

How old is James Bingham?

James Bingham is 53, he's been the Chief Development Officer of Nextcure Inc since 2018. There are 18 older and 2 younger executives at Nextcure Inc. The oldest executive at Nextcure Inc is David Kabakoff, 72, who is the Independent Chairman of the Board.

What's James Bingham's mailing address?

James's mailing address filed with the SEC is C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD, 20705.

Insiders trading at Nextcure Inc

Over the last 6 years, insiders at Nextcure Inc have traded over $0 worth of Nextcure Inc stock and bought 1,475,000 units worth $25,387,500 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Chau Quang Khuong, and Timothy M Shannon. On average, Nextcure Inc executives and independent directors trade stock every 48 days with the average trade being worth of $233,653. The most recent stock trade was executed by Kevin N. Heller on 14 July 2020, trading 27,229 units of NXTC stock currently worth $48,195.

What does Nextcure Inc do?

nextcure, inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. its lead product candidate is nc318, which is in phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. the company is also developing nc410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called leukocyte-associated immunoglobulin-like receptor 1. its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the b7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. nextcure, inc. has a license agreement with yale university; and a research and development col

Nextcure Inc executives and stock owners

Nextcure Inc executives and other stock owners filed with the SEC include:

• Steven Cobourn,
  Chief Financial Officer
• Michael S. Richman MSBA,
  Co-Founder, CEO, Pres & Director
• Michael S. Richman,
  Co-Founder, CEO, Pres & Director
• Michael Richman,
  President, Chief Executive Officer, Director
• Sol Langermann,
  Chief Scientific Officer
• Dr. Solomon Langermann Ph.D.,
  Chief Scientific Officer
• David Kabakoff,
  Independent Chairman of the Board
• Stephen Webster,
  Independent Director
• Briggs Morrison,
  Independent Director
• Timothy Mayer,
  Chief Operating Officer
• Chau Khuong,
  Independent Director
• Elaine Jones,
  Independent Director
• Stella Xu,
  Independent Director
• John Houston,
  Director
• Garry Nicholson,
  Independent Director
• Linda Liu,
  Senior Vice President - Research
• James Bingham,
  Chief Development Officer
• Sourav Kundu Ph.D.,
  Sr. VP of Devel. & Manufacturing
• Dr. Han Myint FACP, M.D.,
  Chief Medical Officer
• Dr. Timothy Mayer Ph.D.,
  Chief Operating Officer
• Steven P. Cobourn CPA, CPA,
  Chief Financial Officer
• Dr. Lieping Chen M.D., Ph.D.,
  Co-Founder & Chairman of Scientific Advisory Board
• Kevin N. Heller,
  Chief Medical Officer
• Venture Partners Ix, L.P.So...,
  
• Advisors Llc Orbi Med Capit...,
  
• X L.P.Canaan Partners X Llc...,
  
• Timothy M Shannon,
  Director
• Judith Li,
  Director
• Anne Elizabeth Borgman,
  
• Ellen Feigal,
  
• Sourav Kundu,
  Sr VP, Dev. & Mfg.
• Han Myint,
  Chief Medical Officer
• Kevin G. Shaw,
  Sr VP, General Counsel